Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4609]

Researchers find evidence that diet can alter the microbiome to affect breast cancer risk

Researchers find evidence that diet can alter the microbiome to affect breast cancer risk

European Commission approves nivolumab plus ipilimumab as first-line treatment for mesothelioma

European Commission approves nivolumab plus ipilimumab as first-line treatment for mesothelioma

Ageing impairs anti-tumour T-cell response via mitochondria dysfunction

Ageing impairs anti-tumour T-cell response via mitochondria dysfunction

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line immunotherapy in advanced bladder cancer

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line...

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with...

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced nasopharyngeal carcinoma

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced...

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer

Clinical trial launched following discovery that psychiatric drug may prevent bowel cancer

Clinical trial launched following discovery that psychiatric drug may prevent bowel cancer

FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma

FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma

More from ecancer